Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM5 trial in multiple myeloma
ISRCTN05622749Phase 3Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bortezomib, lenalidomide, doxorubicin, cyclophosphamide and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Response to treatment after induction therapy and Progression-free survival. Started Jul 2010; status: completed.
02
Drugs
bortezomiblenalidomidedoxorubicincyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN05622749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN05622749.